Golimumab shows higher treatment persistence rates in patients with IMRD
MSD has announced the publication of the results of a retrospective analysis of a large Swedish prescription registry study, which described real-world treatment persistence in patients with immune-mediated rheumatic disease (IMRD) newly treated with different subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFi).
Click on this link for more information.
